Damaris Vega, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1447351176
Payments from drug & device makers
Across 3,373 payments — averaging $3661.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$8M
- Genentech, Inc.$856K
- Boehringer Ingelheim$590K
- Pfizer$572K
- AstraZeneca$350K
- Lilly USA, LLC$340K
- plus $1.7M from 54 others
Across 30 payments — averaging $7093.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Applied Therapeutics, Inc.$131K
- Eli Lilly$81K
What the payments were for
- Consulting fees$11,3552%
- Speaking & faculty fees$447,51179%
- Travel & lodging$68,08812%
- Food & beverage$37,6857%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$171,230
- TRULICITY$83,351
- Ozempic$75,890
- JARDIANCE$46,464
- RYBELSUS$45,452
- Tresiba$18,674
- FARXIGA$11,426
- Pogo Automatic Blood Glucose Monitoring System$5,281
- DEXCOM G7 GSS (161)$4,331
- Xultophy 100/3.6$3,629
- INVOKANA$2,457
- DEXCOM STELO GLUCOSE BIOSENSOR$2,416
- Saxenda$1,620
- Victoza$1,604
- Minimed 670G System$993
- iLet Bionic Pancreas$700
- t:slim X2 insulin pump$550
- DEXCOM G6 TRANSMITTER$450
- Omnipod$334
- t-slim insulin pump$250
How this compares
$12,349,384 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 532 | $832,268 |
| MounjaroTirzepatide | 361 | $504,907 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 143 | $198,359 |
| JardianceEmpagliflozin | 130 | $167,269 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 126 | $146,804 |
| TrulicityDulaglutide | 93 | $140,260 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $105,819 |
| Xigduo XrDapaglifloz Propaned/Metformin | 83 | $75,438 |
| ProliaDenosumab | 41 | $71,035 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $57,186 |
| FarxigaDapagliflozin Propanediol | 36 | $49,519 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $40,756 |
| Tresiba Flextouch U-100Insulin Degludec | 80 | $39,952 |
| GlyxambiEmpagliflozin/Linagliptin | 35 | $38,993 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 26 | $38,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Xultophy 100-3.6, Rybelsus, Novolog | $154,003 | $926,512633 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $340,255 | $671,648546 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi, Trijardy Xr, Tradjenta | $589,556 | $472,078358 claims |
| AmgenProlia | $258,665 | $71,03541 claims |
| MerckJanumet Xr, Januvia | $15,343 | $69,03862 claims |
| AstraZenecaFarxiga | $349,670 | $49,51936 claims |
| BayerKerendia | $160,005 | $28,82424 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,259 | $25,28520 claims |
| PfizerGenotropin | $571,613 | $19,75011 claims |
| AbbVieSynthroid | $169,870 | $14,102151 claims |
| Esperion Therapeutics, Inc.Nexlizet | $328 | $10,79812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Maria CabanillasHouston$16.4M
- Amer Al KaradshehHouston$8.8M
- Amir HassanHouston$5.2M
- Camilo JimenezHouston$5M
- Rocio HarbisonHouston$3.2M
- Gerardo BuesoHouston$1.2M
- Veena WatweHouston$976K
- Andres SplenserHouston$923K
- Prashant KoshyHouston$795K
- Laila TabatabaiHouston$780K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.